US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Inify Laboratories: Notice of Extraordinary General Meeting and proposed fully guaranteed equity issue with proceeds of SEK 150 million

STOCKHOLM – November 15, 2024 – reference is made to the stock exchange announcement made by Inify Laboratories AB (“Inify” or the “Company”) on 23 October 2024 regarding expansion to the UK and a potential share issue of approximately SEK 150 million. The Company will in a separate press release call for an Extraordinary General Meeting (the “EGM”) to be held on 6 December 2024 at 10:00 CET to resolve to authorize the board of directors to resolve on the issuance of new shares. Provided that the EGM resolves to authorize the board of directors to resolve on the issuance of new shares,

Inify Laboratories - notice of Extraordinary General Meeting on December 6, 2024

Stockholm – November 15, 2024 - Inify Laboratories AB (publ), a unique laboratory service provider within pathology and cancer diagnostics, hereby invites its shareholders to Extraordinary General Meeting on December 6, 2024. Please find attached the invitation including attachment, agenda and details on how to register and vote. The invitation is also available on the company's website: www.inify.com. For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann-charlotte.linderoth@inify.com or: ir@inify.com.   ###   The future of pathology Inify

Inify Laboratories enter a research partnership with the Department of Molecular Medicine and Surgery at Karolinska Institutet aiming to advance precision diagnostics within prostate cancer

STOCKHOLM – November 05, 2024 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, is proud to announce a partnership with the ProMort research team at Karolinska Institutet, aimed at transforming prostate cancer diagnostics. The primary objective of this collaboration is to improve the precision of prostate cancer diagnosis through AI-driven image analysis.“When our ProMort team started the discussions with Inify, we quickly realized the power of their organization and technology. A collaboration has great potential to further advance the

Panel talk about Inify’s third quarter 2024

Inify Laboratories have decided to establish its operation to the United Kingdom and expand diagnostics to the gastrointestinal field. One of the major challenges in the UK is long and unpredictable response times and varying quality in prostate cancer care. The market is six times larger than Sweden´s in terms of patient volume, with approximately 120,000 patients annually who require diagnosis. "The national health care system NHS in the UK has a high focus on pathways for patients that are going through cancer investigations, and here is exactly where we provide unique

Inify Laboratories: Establishment in the United Kingdom and expansion into gastrointestinal diagnostics

STOCKHOLM - October 23, 2024 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, has after extensive market mapping decided to establish operations in the United Kingdom (UK).   “After our successful launch in Sweden, where we now have around 80% of the Stockholm market share, the time is right to expand. The UK market is estimated to be six times larger than Sweden’s in terms of patient volume, with approximately 120,000 patients annually who require diagnosis,” says CEO Fredrik Palm in Inify Laboratories.   The company has

Inify Laboratories gets honorable mention by the Royal Swedish Academy of Engineering Sciences (IVA) at the Smart Industry business competition 2024

STOCKHOLM - October 10, 2024 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology received an honorable mention by the Royal Swedish Academy of Engineering Sciences (IVA) during the Smart Industry business competition 2024 during the award ceremony on October 9 in Gothenburg.“Inify receives an honorable mention in the Smart Industry business competition 2024 for their ultramodern laboratory that combines an industrial approach with innovations within healthcare processes. Their technology is based on niche digital applications with unique

Panel talk about Inify’s second quarter 2024

"We are saving weeks in waiting time for patients to get the diagnosis". This and more value that Inify Laboratories can provide to its customers from day one is highlighted in this panel talk about the second quarter of 2024 with CEO Fredrik Palm, Laboratory Director Emelie Edvigsson and Ole Eikeland.Inify Laboratories continued to deliver strong growth with sales of SEK 3.6 million in the quarter – up 62% compared to Q1. By the end of June, the laboratory had been open for over a year and had diagnosed more than 1,000 patients. More details about the laboratory operations and its

INIFY Laboratories: 62% revenue growth and strong international interest

STOCKHOLM - August 21, 2024 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, continues to deliver strong growth, with sales of SEK 3.6 million in the quarter – up 62% compared to the previous quarter. Total sales for the first half of the year amounted to SEK 5.8 million, with a cash balance at the end of the second quarter of SEK 46,1 million. “We have diagnosed more than 1,000 patients since the opening of our first laboratory and our market share in Sweden has grown to around 5%, which means that the continued growth potential in

Inify Laboratories AB (publ) – summary of Annual General Meeting

Inify Laboratories AB, corp. no. 559345-4431, held its ordinary Shareholders’ Annual General Meeting at the company's premises on May 14, 2024. A total of 30,133,104 shares were represented at the Annual General Meeting, corresponding to 66.61% of the total number of shares and votes. The AGM resolved, with the required majority, on all matters in accordance with the Board of Directors's published proposal. Below is a summary of the main decisions made, for further details please refer to the notice available on the company's website.   Adoption of the accounts The Annual General

Inify Laboratories - More diagnoses delivered in the first quarter than in the whole of 2023

STOCKHOLM - April 24, 2024 - Inify Laboratories, a unique laboratory service provider within pathology and cancer diagnostics, saw a 184% increase in sales in Q1 2024, compared to the previous quarter. “What we see now is the result of many years of preparation. More diagnoses were delivered in the first quarter alone than in the whole of 2023. The company’s whole organization is ready for the significant increase in sales that we foresee both this year, and the years to come,” says CEO Fredrik Palm at Inify Laboratories. Inify is experiencing a great deal of interest from new

Inify Laboratories - Annual Report 2023

Stockholm – April 11, 2024 – Inify Laboratories, a unique laboratory service provider within pathology and cancer diagnostics, presents its Annual Report for the fiscal year ended December 31, 2023. The annual report is attached to this press release and is also available on the company’s website: www.inify.com. Printed copies of the report will be distributed upon request sent to e-mail: ir@inify.com. For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann-charlotte.linderoth@inify.com or: ir@inify.com   ###     About Inify Laboratories Inify

Inify Laboratories – notice of Annual General Meeting on May 14, 2024

Stockholm – April 11, 2024 – Inify Laboratories AB (publ), a unique laboratory service provider within pathology and cancer diagnostics, hereby invites its shareholders to Annual General Meeting on May 14, 2024. Please find attached the invitation including agenda and details on how to register and vote. The invitation is also available on the company’s website: www.inify.com. For inquiries, please contact CFO Ann-Charlotte Linderoth at e-mail: ann-charlotte.linderoth@inify.com or: ir@inify.com.   ###     About Inify Laboratories Inify Laboratories provides cancer

Panel talk about Inify’s fourth quarter 2023

Listen to CEO Fredrik Palm and Sales & Marketing Manager Maria Holmberg in this panel talk, moderated by Ole Eikeland, where they talk about the immediate effects of using Inify's services, where customers have been able to shorten time for result to patients from 21 to 7 days, how word-of-mouth marketing has led to incoming calls plus how AI supports the patologists making the cancer diagnosis.Inify Laboratories saw important pieces fall into place during the fourth quarter of 2023, the foremost being the attainment of accreditation as a medical laboratory. This paved the way for making

Foresees a noticeable increase of customers, volume, and sales in 2024

STOCKHOLM - February 29, 2024 - Inify Laboratories, a unique laboratory service provider within pathology and cancer diagnostics, saw important pieces fall into place during the fourth quarter, the foremost being our attainment of accreditation as a medical laboratory. This paved the way for making Inify’s diagnostic service fully available to both private and public healthcare providers, resulting in a sales growth of 176% compared to the third quarter. “I dare to claim that our operations are unique – in Sweden, and internationally. Our ambition is to stay at the forefront in terms of

Inify Laboratories receives accreditation as a medical laboratory

STOCKHOLM - November 6, 2023 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics in pathology, has received accreditation as a medical laboratory according to the ISO 15189 standard.   "To be accredited within five months of launching a completely unique laboratory service for cancer diagnostics must be some kind of record. It is yet another confirmation of the ability, quality awareness, and breadth of knowledge that Inify possesses," says Fredrik Palm, CEO of Inify Laboratories.   "For Inify, this is proof that our business lives up to the high

Continuous diagnostic operation and very positive feedback from customers

STOCKHOLM - October 24, 2023 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, has had a continuous inflow of patient samples for diagnosis, which is of paramount importance for the optimization of both the internal laboratory system and the interaction with customers. “We have analyzed prostate biopsies on a daily basis since we opened our first laboratory in June. The feedback has been very positive, and we are experiencing an increasing interest in our services among urologists and other stake holders. The awareness about Inify

Panel talk about Inify’s second quarter 2023

The second quarter of 2023 marked an important milestone for Inify Laboratories - the opening of the laboratory in Solna/Stockholm to offer prostate cancer diagnostic services for urology clinics and their patients.Listen to CEO Fredrik Palm and Laboratory Manager Emelie Edvigsson in this panel talk, led by Ole Eikeland, where they explain some of the success factors for Inify's first laboratory. Some highlights include the positive customer feedback, the strategic partnerships and the importance of a tailor-made Laboratory Information System, LIS, to support the workflow instead of forcing

Inify Laboratories - Successful laboratory launch in Q2 with delivery of first prostate cancer diagnosis

STOCKHOLM - August 23, 2023 - Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, successfully launched in the second quarter 2023.   “We launched our laboratory service in mid-June, completely according to plan. The interest is high, and we already see the first revenue streams,” says CEO Fredrik Palm at Inify Laboratories.   Since the opening, the response time – from the collection of samples until the customers have an electronically structured, easy-to-read report – has been well within the promised time.   “The secret

Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, July 5, 2023; Inify Laboratories AB (publ.) has been notified that the following transaction has been completed by a close associate to a primary insider in Inify: Monsun AS, a Norwegian company controlled by Magne Jordanger, board member and primary insider in Inify, has bought 650,000 shares in Inify at an average price of NOK 10.00 per share. After the transaction, Monsun AS holds 986,950 shares. This information is subject to the disclosure requirements in the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading

Finansavisen highlights Inify Laboratories

Norwegian financial newspaper Finansavisen highlights Inify Laboratories in a report from the laboratory in Solna. CEO Fredrik Palm and Chief Medical Officer Claes Lindh discuss challenges in healthcare, market potential and what makes Inify so unique. The article describes how the laboratory is now fully operational and receiving patient samples in the form of prostate biopsies. These are diagnosed with the assistance of AI and a carefully controlled laboratory process, that leads to shorter, predictable waiting times for patients and high and consistent quality in the diagnostics.

Successful launch of Inify Laboratories’ services, with first patient cases diagnosed

“The beginning of a paradigm shift within pathology”   STOCKHOLM – June 20, 2023 – Inify Laboratories, a unique laboratory service that provides cancer diagnostics within pathology, announces the opening of its first laboratory, having delivered its first prostate cancer diagnoses.   “We are extremely proud to have launched successfully and according to plan. We have now started to deliver our unique diagnostic services to our first customers here in Sweden,” says Fredrik Palm, CEO at Inify Laboratories.   The company offers specialized pathology diagnostics for prostate

Inify Laboratories AB (publ) – summary of Annual General Meeting

Inify Laboratories AB, corp. no. 559345-4431, held its ordinary Shareholders’ Annual General Meeting at the company's premises on May 16, 2023. A total of 34,075,774 shares were represented at the Annual General Meeting, corresponding to 75.3% of the total number of shares and votes. The AGM resolved, with the required majority, on all matters in accordance with the Board of Directors's published proposal. Below is a summary of the main decisions made, for further details please refer to the notice available on the company's website.   Adoption of the accounts The Annual General

Inify Laboratories - Strong market interest and launch on track

STOCKHOLM – April 26[th], 2023 – Inify Laboratories, a fully integrated digital ultramodern laboratory service that provides cancer diagnostics within pathology, is on track for launch at the end of Q2 this year. “We continue to make good progress with our laboratory. This first quarter has been dominated by work with installation, testing and documentation, to get the laboratory ready to serve public and private clinics with prostate cancer diagnostics,” says CEO Fredrik Palm at Inify Laboratories. The company sees great interest from potential customers, and has received positive

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media